Elutia (ELUT) Projected to Announce Quarterly Earnings on Thursday

Elutia (NASDAQ:ELUT) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $1.00 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Elutia (NASDAQ:ELUT) last announced its earnings results on Thursday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Elutia had a negative return on equity of 407.37% and a net margin of 426.93%. The firm had revenue of $2.43 million during the quarter, compared to the consensus estimate of $2.90 million.

Elutia Stock Performance

Shares of NASDAQ:ELUT opened at $0.84 on Thursday. The firm has a market capitalization of $37.20 million, a P/E ratio of 0.88 and a beta of 0.84. The stock has a 50 day moving average price of $0.84 and a 200-day moving average price of $0.97. Elutia has a 52-week low of $0.50 and a 52-week high of $1.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Elutia from a “sell (d)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Elutia Company Profile

Elutia Inc is a medical technology company focused on developing and commercializing biologic products designed to support tissue healing and improve the performance of implantable medical devices. The company combines human tissue-based materials with drug-delivery and regenerative medicine technologies.

Its product portfolio includes biologic envelopes used to protect and support cardiac implantable electronic devices, including pacemakers and defibrillators. Elutia also develops tissue matrices and other biologic products for orthopedic, wound care and related surgical applications, with products intended to support soft-tissue repair, reconstruction and healing.

The company was formerly known as Aziyo Biologics and adopted the Elutia name as part of its broader focus on bioelectronic medicine and regenerative healthcare.